Cadila HealthCare Ltd (Zydus Cadila)

Zydus - Dedicated to Life

About us –
Cadila Healthcare Limited (also known as Zydus Cadila) is an Indian multinational
pharmaceutical company headquartered in Ahmedabad, Gujarat, India. It is a
manufacturer of generic drugs. With in-depth domain expertise in the field of
healthcare, it has strong capabilities across the spectrum of the pharmaceutical
value chain. From formulations to active pharmaceutical ingredients and animal
healthcare products to wellness products, Zydus has earned a reputation amongst
Indian pharmaceutical companies for providing comprehensive and complete
healthcare solutions. The Zydus group has manufacturing sites and research
facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh
and Sikkim in India and in the US and Brazil.

Zydus’ global business has a strong presence in the regulated markets of the US,
Europe (France and Spain) and in the high-profile markets of Latin America and
South Africa. It is also present in a big way in 25 other emerging markets worldwide. 

Cadila was founded in 1952 by Ramanbhai Patel (1925–2001), formerly a lecturer in

the L.M. College of Pharmacy, and his business partner Indravadan Modi. 

The company generated a revenue of ₹ 7,104.30 crore ($1 billion USD) in 2019.
The revenues increased to ₹ 1,796 crore and posted a net profit of ₹ 398 crore
for the quarter ended June 2020.

Innovation & Research - As a research-based pharmaceutical company, Zydus'

Innovation programme is spearheaded by 1400 researchers across 19 sites, working
on differentiated medicines for the future. From NCEs to vaccines, biosimilars and
niche technologies, the group is exploring different ideas, concepts and continuously
innovating.

Major Areas Of Research – New Chemical Entities Research, Biologics, Vaccines

(Currently working on Covid 19 vaccine).
New Chemical Entities - The Zydus Research Centre (ZRC) is the dedicated
research arm of the Zydus Group. With its team of over 400 research professionals,
ZRC spearheads the group’s quest of creating healthier and happier communities
globally. Spread over an area of over 4,75,000 sq ft, ZRC is working on cutting edge
technologies in different scientific disciplines to discover novel therapeutic agents.
The centre has capabilities to conduct drug discovery & development from concept
to IND enabling preclinical and clinical studies. In 2013, the group was the first to
identify, develop and launch LipaglynTM (Saroglitazar) the novel drug to treat diabetic
dyslipidemia – a global, unmet healthcare need. Lipaglyn is the first NCE from an
Indian research pipeline to move from the lab to the market. It offers dual benefits of
lipid and glycemic control in one single molecule. It is an innovation that has helped
over 700000 people suffering from diabetic dyslipidemia in India lead healthier lives.

Biologics – Exemptia – World’s first biosimilar of Adalimumab – It provides a new

lease of life to Indian patients of inflammatory arthritis, who did not have access to
this revolutionary therapy so far.

Vaccines - The Vaccine Technology Centre (VTC) is the vaccine research centre of
the Zydus Group. VTC has two state-of-the-art R & D Centres, one located in
Catania, Italy and the other in Ahmedabad, in the western part of India. The Vaccine
Technology Centre (VTC) has been developing vaccines for the basic vaccine
programmes such as Diphtheria, Pertussis, Tetanus, Haemophilus Influenzae type
B, Hepatitis B, Measles, Mumps, Rubella, Varicella, Influenza and Typhoid fever. In
addition, VTC is developing new vaccines such as Human Papilloma Virus,
Leishmaniasis, Malaria, Haemorrhagic Congo Fever, Ebola and Japanese
Encephalitis. Zydus has indigenously developed, manufactured and launched India's
first Tetravalent Inactivated Influenza vaccine, VaxiFlu – 4. The vaccine provides
protection from the four influenza viruses- H1N1, H3N2, Type B (Brisbane) and Type
B (Phuket). Zydus’ rabies vaccine manufacturing facility has received WHO pre-
qualification, and is one of the largest rabies manufacturing facilities in India.

Company’s Mission – Creating Healthier Communities – Zydus Cadila is dedicated

to life, in all its dimensions. Our world is shaped by the passion for innovation,
commitment to partners and concern for people in an effort to create healthier
communities, globally.

Vision – Opening up new pathways through innovation and quality excellence, Zydus
to be a research-based company by end 2020.

Awards & Recognitions

 The Overall India Pharma Excellence Award and the India Pharma Innovation
of the Year Award from the Department of Pharmaceuticals, Government of
India.
 The CII Industrial Innovation Grand Jury Award of being the Most Innovative
Company of the Year.
 Declared the most Innovative Pharmaceutical Company by Thomsun Reuters.
 Amongst the top 3 finalists at the Time India Awards 2017 in the ‘Global
Manufacturer for the Year’ category
 Amongst the top five companies worldwide at the FT ArcelorMittal Boldness in
Business Awards 2014 in the Developing Markets category
 Declared as the ‘Emerging Company of the Year’ by the Economic Times
Awards for Corporate Excellence 2010.

Competitors

Aurobindo – 22000 employees, $ 2 Billion revenue

Lupin – 20000 employees, $ 2.3 Billion revenue

GSK Pharma – 100000 employees, 3375.4 crore GBP

Glenmark – 14027 employees, $ 1.4 Billion revenue

Cipla – 25845 employees, $ 2.3 Billion revenue

Mankind Pharma – 16000 employees, Rs 5600 crore revenue

Dr Reddy’s Lab – 21966 employees, $ 2 Billion revenue

Fareva – 12000 employees, $ 2 Billion revenue

Teva Pharma – 44000 employees, Rs 1890 crore revenue

Sun Pharma – 17501 employees, $ 4 billion revenue

Growth of Zydus Cadila –

From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant
financial growth and registered a turnover of over Rs. 14,253 crores in FY20.

Zydus Cadila in the news –

 India needs to invest Rs 5K cr to give all Indians Covid vaccine: Zydus

Cadila Chairman. Read more at:
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceut
icals/india-needs-to-invest-rs-5k-cr-to-give-all-indians-covid-vaccine-zydus-
cadila-chairman/articleshow/78239946.cms?
utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

 Zydus Cadila begins human clinical trials of COVID-19 vaccine

candidate
Read more at:
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceut
icals/zydus-cadila-begins-human-clinical-trials-of-covid-19-vaccine-
candidate/articleshow/76973516.cms?
utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

 Zydus promise: Covid-19 vaccine by March